HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,460 | +5.9% | 300 | 0.0% | 0.00% | – |
| Q2 2023 | $10,821 | -5.6% | 300 | 0.0% | 0.00% | – |
| Q1 2023 | $11,457 | -84.5% | 300 | -76.9% | 0.00% | -100.0% |
| Q4 2022 | $73,970 | +45.0% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $51,000 | -10.5% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $57,000 | +307.1% | 1,300 | +271.4% | 0.00% | – |
| Q3 2021 | $14,000 | -12.5% | 350 | 0.0% | 0.00% | – |
| Q2 2021 | $16,000 | -100.0% | 350 | -79.4% | 0.00% | -100.0% |
| Q1 2021 | $70,874,000 | +472393.3% | 1,700 | +385.7% | 0.00% | – |
| Q4 2020 | $15,000 | -64.3% | 350 | -85.4% | 0.00% | -100.0% |
| Q4 2019 | $42,000 | +13.5% | 2,400 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $37,000 | -24.5% | 2,400 | -16.5% | 0.00% | -50.0% |
| Q2 2019 | $49,000 | -14.0% | 2,875 | -8.1% | 0.00% | -33.3% |
| Q3 2018 | $57,000 | +7.5% | 3,130 | -0.3% | 0.00% | 0.0% |
| Q2 2018 | $53,000 | – | 3,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |